AR091706A1 - Formulaciones de laquinimod sin agentes alcalinizantes - Google Patents

Formulaciones de laquinimod sin agentes alcalinizantes

Info

Publication number
AR091706A1
AR091706A1 ARP130102429A AR091706A1 AR 091706 A1 AR091706 A1 AR 091706A1 AR P130102429 A ARP130102429 A AR P130102429A AR 091706 A1 AR091706 A1 AR 091706A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
multiple sclerosis
stable pharmaceutical
subject suffering
amount
Prior art date
Application number
Other languages
English (en)
Spanish (es)
Inventor
Sarfati Gadi
Safadi Muhammad
Lovinger Ioana
Licht Danit
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of AR091706A1 publication Critical patent/AR091706A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP130102429 2012-07-11 2013-07-08 Formulaciones de laquinimod sin agentes alcalinizantes AR091706A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261670268P 2012-07-11 2012-07-11

Publications (1)

Publication Number Publication Date
AR091706A1 true AR091706A1 (es) 2015-02-25

Family

ID=49914501

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130102429 AR091706A1 (es) 2012-07-11 2013-07-08 Formulaciones de laquinimod sin agentes alcalinizantes

Country Status (19)

Country Link
US (1) US20140018386A1 (https=)
EP (1) EP2872141A4 (https=)
JP (1) JP2015527321A (https=)
KR (1) KR20150036553A (https=)
CN (1) CN104470519A (https=)
AR (1) AR091706A1 (https=)
AU (1) AU2013290274A1 (https=)
BR (1) BR112015000321A2 (https=)
CA (1) CA2873230A1 (https=)
EA (1) EA201590193A1 (https=)
HK (1) HK1209054A1 (https=)
IL (1) IL236229A0 (https=)
MX (1) MX2015000398A (https=)
NZ (1) NZ630241A (https=)
SG (2) SG10201700198VA (https=)
TW (1) TW201408299A (https=)
UA (1) UA115555C2 (https=)
WO (1) WO2014011750A1 (https=)
ZA (1) ZA201500287B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2445451T3 (es) 2007-12-20 2014-03-03 Teva Pharmaceutical Industries, Ltd. Preparaciones estables de laquinimod
CN106063787A (zh) 2012-02-03 2016-11-02 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
JP2015535287A (ja) 2012-11-07 2015-12-10 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドのアミン塩
NZ630427A (en) 2013-03-14 2017-06-30 Teva Pharma Crystals of laquinimod sodium and improved process for the manufacture thereof
EA201692180A1 (ru) 2014-04-29 2017-08-31 Тева Фармасьютикал Индастриз Лтд. Лахинимод для лечения пациентов с рецидивирующе-ремиттирующим рассеянным склерозом (рррс) с высоким статусом инвалидизации
CN107823168A (zh) * 2017-10-25 2018-03-23 北京素维生物科技有限公司 一种快速溶解的片剂及其制备方法
CN107823150A (zh) * 2017-10-25 2018-03-23 北京素维生物科技有限公司 一种可快速分散的片剂及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
SE0400235D0 (sv) * 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US7884208B2 (en) * 2005-10-19 2011-02-08 Teva Pharmaceutical Industries, Ltd. Crystals of laquinimod sodium, and process for the manufacture thereof
RS52169B (sr) * 2006-06-12 2012-08-31 Teva Pharmaceutical Industries Limited Stabilni preparati lakvinimoda
ES2445451T3 (es) * 2007-12-20 2014-03-03 Teva Pharmaceutical Industries, Ltd. Preparaciones estables de laquinimod
WO2010070449A2 (en) * 2008-12-17 2010-06-24 Actavis Group Ptc Ehf Highly pure laquinimod or a pharmaceutically acceptable salt thereof
WO2013016686A1 (en) * 2011-07-28 2013-01-31 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and interferon-beta

Also Published As

Publication number Publication date
NZ630241A (en) 2017-09-29
ZA201500287B (en) 2016-10-26
EA201590193A1 (ru) 2015-04-30
TW201408299A (zh) 2014-03-01
IL236229A0 (en) 2015-01-29
US20140018386A1 (en) 2014-01-16
EP2872141A4 (en) 2016-01-13
BR112015000321A2 (pt) 2017-06-27
SG11201407688QA (en) 2014-12-30
WO2014011750A1 (en) 2014-01-16
JP2015527321A (ja) 2015-09-17
EP2872141A1 (en) 2015-05-20
HK1209054A1 (zh) 2016-03-24
WO2014011750A8 (en) 2014-12-04
MX2015000398A (es) 2015-04-10
SG10201700198VA (en) 2017-02-27
AU2013290274A1 (en) 2014-11-27
KR20150036553A (ko) 2015-04-07
UA115555C2 (uk) 2017-11-27
CN104470519A (zh) 2015-03-25
CA2873230A1 (en) 2014-01-16

Similar Documents

Publication Publication Date Title
AR091706A1 (es) Formulaciones de laquinimod sin agentes alcalinizantes
MX2020004023A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
UA109991C2 (xx) Карбаматні сполуки, їх отримання і застосування
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
BR112015027282A2 (pt) fenfluramina para uso no tratamento de síndrome de dravet
MX2019003467A (es) Formulaciones y metodos para la administracion vaginal de antiprogestinas.
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
MY176246A (en) Compositions for oral administration of zoledronic acid or related compounds for treating disease
PH12016501965A1 (en) S1p modulator immediate release dosage regimen
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
PE20151526A1 (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
MX2016000294A (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
MX2015000485A (es) Tratamiento de esclerosis multiple con una combinacion de laquinimod y fampridina.
UY35890A (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
MX2015007164A (es) Uso de estracto de fenogreco para mejorar la libido femenina.
ZA201906153B (en) Pharmaceutical compositions for combination therapy
BR112014030288A8 (pt) composição farmacêutica, uso da mesma, e, uso de metanossulfonilacetonitrila
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
MX366118B (es) Combinacion sinergistica de paracetamol/celecoxib para el tratamiento de dolor inflamatorio.
CO7170180A2 (es) Composición farmacéutica inyectable de dexketoprofeno y tramadol
MX2016001177A (es) Tratamiento de esclerosis multiple con la combinacion de laquinimod y flupirtina.
UY35748A (es) Terapia combinada con laquinimod para el tratamiento de la esclerosis múltiple
CY1124107T1 (el) Συνδυασμος αδαπαλενης και υπεροξειδιου του βενζολιου για τη θεραπευτικη αντιμετωπιση της σοβαρης ακμης

Legal Events

Date Code Title Description
FB Suspension of granting procedure